"effect was due to the ability of VPA to attenuate platelet cytoskeletal rearrangement via inhibition of glycogen synthase kinase 3β (GSK3β), ... Similarly, treating platelets with lithium, another GSK3β inhibitor, also halted cytoskeletal rearrangement."
"effect was due to the ability of VPA to attenuate platelet cytoskeletal rearrangement via inhibition of glycogen synthase kinase 3β (GSK3β), ... Similarly, treating platelets with lithium, another GSK3β inhibitor, also halted cytoskeletal rearrangement."
RT @renesugar: @angryhacademic https://t.co/CCNLhtoOp8 "Lithium 10mg po qd" Lithium orotate (4.8 mg lithium): https://t.co/e8BhDFA2YT htt…
@angryhacademic https://t.co/CCNLhtoOp8 "Lithium 10mg po qd" Lithium orotate (4.8 mg lithium): https://t.co/e8BhDFA2YT https://t.co/oBJB2Q7Cf5 Like VPA, lithium limits the release of sCD40L from platelets: https://t.co/NaXq2mOQ7I